|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:antidote
|
gptkb:idarucizumab
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:ATCCode
|
B01AE07
|
|
gptkbp:bioavailability
|
6.5%
|
|
gptkbp:brand
|
gptkb:Pradaxa
|
|
gptkbp:CASNumber
|
211914-51-1
|
|
gptkbp:contraindication
|
patients with active pathological bleeding
patients with mechanical prosthetic heart valves
|
|
gptkbp:drugInteraction
|
gptkb:NSAIDs
anticoagulants
antiplatelet agents
P-glycoprotein inhibitors
|
|
gptkbp:eliminatedIn
|
urine
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasDrugBankCategory
|
gptkb:anticoagulant
|
|
gptkbp:hasInChIKey
|
PTZSUBHDPIDFOT-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C34H41N7O5
|
|
gptkbp:hasReversalAgent
|
gptkb:idarucizumab
|
|
gptkbp:hasSMILES
|
CC(C)N1C(=O)NC(C(=O)N(C2CC2)C(=O)N(C)C3=CC=CC=C3)C1=O
|
|
gptkbp:hasUNII
|
2ZC53Y6Z98
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB01586
|
|
gptkbp:indication
|
treatment and prevention of deep vein thrombosis
treatment and prevention of pulmonary embolism
prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
direct thrombin inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
627.74
|
|
gptkbp:name
|
gptkb:Dabigatran
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
35%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
148124
D08167
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
dyspepsia
gastrointestinal upset
|
|
gptkbp:status
|
true
|
|
gptkbp:target
|
gptkb:thrombin_(F2)
|
|
gptkbp:toxicity
|
overdose may cause severe bleeding
|
|
gptkbp:bfsParent
|
gptkb:ursodeoxycholic_acid
|
|
gptkbp:bfsLayer
|
6
|